Evidence map›Paper›PMID 39272162›Full record

ArticleRadiation oncology (London, England)2024

The significance of risk stratification through nomogram-based assessment in determining postmastectomy radiotherapy for patients diagnosed with pT

Chao Wei, Jie Kong, Huina Han, Xue Wang, Zimeng Gao, Danyang Wang, Andu Zhang, Jun Zhang, Zhikun Liu

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Chao WeiDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Jie KongDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Huina HanDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Xue WangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Zimeng GaoDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Danyang WangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Andu ZhangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Jun ZhangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Zhikun LiuDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China. zhikunliu1978@163.com.

Funding

Hebei Province medical science research project 20240090
6 · The paper itself

Abstract

objectiveTo explore the high-risk factors affecting the prognosis of pT

methodThe clinical data of 936 patients with pT

resultThe median follow-up period was 98 months, Patients who received PMRT demonstrated significantly improved 5-year and 8-year OS and DFS compared to those who did not (P < 0.001). Multivariate analysis revealed that age, primary tumor site, positive lymph node, stage, and Ki-67 level independently influenced OS, while age, primary tumor site, and stage independently affected DFS. PMRT drastically enhanced OS in the high-risk group (P = 0.001), but did not confer benefits in the low-risk and intermediate risk groups (P = 0.057, P = 0.099). PMRT led to a significant improvement in disease-free survival (DFS) among patients in the intermediate and high-risk groups (P = 0.036, P = 0.001), whereas the low-risk group did not experience a significant benefit (P = 0.475).

conclusionAge ≤ 40 years, tumor located in the inner quadrant or central area, T

Indexed as

Breast NeoplasmsMastectomyNomogramsAdultAgedFemaleHumansMiddle AgedNeoplasm StagingPrognosisRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentSurvival RateBreast cancerMastectomyNomogram modelpN1PrognosisRadiotherapy

Identifiers

PMID39272162
PMCPMC11396491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.